Sanofi Strengthens Monoclonal Antibody Access With $560 Million Regeneron Deal
This article was originally published in The Pink Sheet Daily
One of the first candidates targeted for development will be an interleukin-6 receptor, a potential competitor to TNF inhibitors, for RA.
You may also be interested in...
Biotech and French partner remain on track to file PCSK9 inhibitor alirocumab this quarter in U.S. and EU; meanwhile, Eylea continues strong sales growth – but launch in second indication, diabetic macular edema, is slow.
Astellas Extends Deal With Regeneron For Antibody Technology Built Around Growing Oncology Portfolio
TOKYO - Astellas has acknowledged that it is a late-comer to the oncology space, but an extension of a non-exclusive license to Regeneron's VelocImmune technology, potentially through 2023, signals the Japanese company's continued effort to become a significant player in the monoclonal antibody space
This first article in a series takes an in-depth look at which pharma/biotech partnerships have the right chemistry to morph from collaboration to merger/acquisition.